Compare VNRX & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNRX | CCEL |
|---|---|---|
| Founded | N/A | 1989 |
| Country | United States | United States |
| Employees | N/A | 76 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Managed Health Care |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.5M | 29.2M |
| IPO Year | 2012 | 2022 |
| Metric | VNRX | CCEL |
|---|---|---|
| Price | $2.73 | $3.50 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 1 |
| Target Price | ★ $1.67 | N/A |
| AVG Volume (30 Days) | ★ 276.1K | 7.0K |
| Earning Date | 05-12-2026 | 04-14-2026 |
| Dividend Yield | N/A | ★ 4.26% |
| EPS Growth | ★ 38.00 | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | $1,727,384.00 | ★ $25,384,279.00 |
| Revenue This Year | $355.66 | N/A |
| Revenue Next Year | $849.08 | N/A |
| P/E Ratio | ★ N/A | $362.00 |
| Revenue Growth | ★ 40.04 | 9.76 |
| 52 Week Low | $0.13 | $2.72 |
| 52 Week High | $3.26 | $5.52 |
| Indicator | VNRX | CCEL |
|---|---|---|
| Relative Strength Index (RSI) | 65.78 | 49.25 |
| Support Level | $0.22 | $3.18 |
| Resistance Level | $2.89 | $3.57 |
| Average True Range (ATR) | 0.29 | 0.22 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 64.18 | 56.99 |
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.